Atlas Trials

Rh-Endostatin Combined With CCRT(50 Gy) Followed by Durvalumab Maintenance for the Treatment of Specific Phase III NSCLC

Clinical trial NCT04613284 · UNKNOWN

Trial details

NCT number
NCT04613284
Sponsor
Shanghai Chest Hospital
Status
UNKNOWN
Phase
Phase 4
Study type
INTERVENTIONAL
Lung Cancer
Start date
2020-12-01
Primary completion
2022-02-01
Enrollment
97

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.